NBY Stock: NovaBay Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live nby stock price $2.81, comprehensive NovaBay Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time nby stock data and investment insights.
Loading chart...
Company Overview
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Company Information
- CEO
- Michael Kazley
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
Contact Information
- Website
- https://novabay.com
- Address
- 2000 Powell Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 0.6)
✓ Lower volatility stock (Beta: 0.48) may provide portfolio stability
Business Model & Strategy
NovaBay Pharmaceuticals, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Michael Kazley, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
NovaBay Pharmaceuticals, Inc. competes in the Biotechnology within the broader Healthcare. With 16.9 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange Arca, NovaBay Pharmaceuticals, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating NovaBay Pharmaceuticals, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for NovaBay Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for NovaBay Pharmaceuticals, Inc.
- ⚠Investors should consider how NovaBay Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
16.93M
P/E Ratio
0.55
Beta
0.48
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 16.93M market capitalization
- Trading Volume: 1.47M shares traded today
- Price Range: 52-week range of $0.46 - $4.44
- Exchange: Listed on New York Stock Exchange Arca
Financial Metrics
Market Analysis for NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. (NBY) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 16.93M, the company represents a significant player in its market. The stock is currently trading at $2.81 with a positivedaily change of 16.32%.
The company's 13 employee base and presence on the New York Stock Exchange Arcaexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 0.55, beta of 0.48, and 52-week price range from $0.46 to $4.44when evaluating investment opportunities.
Why Invest in NovaBay Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange Arca)
- • Experienced leadership under Michael Kazley
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.